News on immunoassay systems and applications.
The company will offer 10 million shares of common stock at $1.00 per share and 50,000 shares of Series B Convertible Preferred Stock at $100.00 per share.
The financing will go toward development of the company's home-based testing technology, which will be initially targeted at fertility testing.
The system will perform 200 multiplexed pathogen ID tests or 40 AST tests in one eight-hour shift on a random access, fully automated benchtop instrument.
DiaSorin's president said that the assay, cleared for use on its Liason instruments, is an addition to the firm's growing specialty menu in the US market.
In a study looking at 4,000-plus men, the test identified patients with elevated PSA levels but low risk of dying from prostate cancer over the next 20 years.
